Xtrava Health Receives Emergency Use Authorization for their Rapid SPERA™ COVID-19 Ag Test
SANTA CLARA, Calif., Oct. 22, 2021 /PRNewswire/ -- Xtrava Health, a health technology company, today announced the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for their SPERA™ COVID-19 Ag Test. The easy-to-use, rapid lateral flow immunoassay directly detects the COVID-19 causing virus in shallow nasal samples authorized for use at the point of care. The test is...
Akeso is rapidly advancing the clinical study of the PD-1/CTLA-4 bispecific antibody Cadonilimab combined with TIGIT monoclonal antibody for the teratment of solid tumors
HONG KONG, Oct. 22, 2021 /PRNewswire/ -- Akeso, one of leading Chinese pharmaceutical innovation company announces that the first patient was dosed in a phase I clinical trial of the Company's independently developed TIGIT monoclonal antibody (AK127) in combination with the Company's global first-in-class Cadonilimab (PD-1/CTLA-4 bi-specific antibody,AK104) for the treatment of advanced or metastatic solid tumors in Australia....
Specialised Therapeutics Enters into a New Supply and Distribution Agreement with Incyte to Launch Two New Cancer Therapies, Tafasitamab and Pemigatinib, in Australia, New Zealand and Singapore
SINGAPORE, Oct. 22, 2021 /PRNewswire/ -- Independent pharmaceutical company Specialised Therapeutics Asia Pte Ltd (ST) will partner with Incyte Biosciences International Sàrl, the Swiss-based affiliate of Incyte (NASDAQ:INCY), to launch and distribute two new medicines for its haematology and oncology portfolios, tafasitamab (sold as Monjuvi® in the United States and Minjuvi® in Europe) and pemigatinib (Pemazyre®). Under the terms of the agreement, Incyte will be...
Kintor Pharma Announces PD-L1/TGF-β dual-targeting antibody (GT90008) Approved for Advanced Solid Tumour Clinical Trial in China
SUZHOU, China, Oct. 21 , 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced that the clinical trial of PD-L1/TGF-β dual-targeting antibody (GT90008) for the treatment of advanced solid tumours was approved by the National Medical Products Administration (NMPA) of China on 21 October 2021. GT90008 is a PD-L1/TGF-β dualtargeting antibody...
Aero HygenX Partners with Ethiopian Airlines for Deployment of Autonomous UV-C Disinfecting Solution
With hygiene in sharp focus, industry support for Aero HygenX continues to grow Chemical-free disinfection via UV-C light offers a safer work environment for staff and is gentler on aircraft interiors A global problem requires global solutions: It is the intention of Aero HygenX to support COVID-19 recovery in regions with lower vaccination rates "As...
Speclipse included in MedTech Outlook rating of top 10 non-invasive device companies
SEOUL, South Korea, Oct. 21, 2021 /PRNewswire/ -- Speclipse, a startup specializing in laser spectroscopic and AI-based medical diagnostic technologies and a member of Born2Global Centre, was recently included in MedTech Outlook's "Top 10 Non Invasive Device Companies" ranking for 2021. Speclipse ranked MedTech Outlook’s “Top 10 Non Invasive Device Companies” ranking for 2021. MedTech Outlook...
INOVIO Announces Collaboration with Colombia; Memorandum of Understanding Focuses on Protecting Against COVID-19 and Supporting Broader Health Preparedness Initiatives
Memorandum of Understanding builds on recent regulatory authorization from INVIMA to conduct INNOVATE Phase 3 trial for INO-4800, INOVIO's COVID-19 vaccine candidate, in Colombia Colombia authorization augments recent regulatory authorizations from Brazil, the Philippines and Mexico to commence its COVID-19 vaccine candidate Phase 3 efficacy trial PLYMOUTH MEETING, Pa., Oct. 21, 2021 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology...
Mentice’s CEO Göran Malmberg to present the company’s interim report at a webcast conference call on October 28 at 9:30 CEST
STOCKHOLM, Oct. 21, 2021 /PRNewswire/ -- Mentice AB (STO: MNTC) announces that the company will present its interim report via webcast conference call with the opportunity for interested parties to ask questions to CEO Göran Malmberg and CFO Gunilla Andersson. To register for the presentation of the interim report for the period July - September 2021, which will be held...
Guangzhou Concord Cancer Center Becomes a Designated Hospital of Social Healthcare Insurance
BEIJING, Oct. 21, 2021 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specializing in cancer care, research and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China, today announced that its Guangzhou Concord Cancer Center ("GCCC"), has obtained the qualifications...
Antengene Enters into a Research Collaboration & License Option Agreement with LegoChem Biosciences for New Antibody-Drug Conjugate Candidates
SHANGHAI and HONG KONG, Oct. 21, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that it has entered into a Research Collaboration and License Option Agreement with LegoChem Biosciences, Inc....
